---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-251073"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T03:55:54.921203+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apellis reports preliminary SYFOVRE Q3 revenue ~$74M; total since launch ~$160M

## Summary
- Approximately $74M in preliminary US net SYFOVRE revenue for Q3 2023; ~$160M total since March 2023 launch.
- More than 100,000 vials (commercial+sample) distributed to date; ~37,000 commercial and 10,000 samples in Q3.
- Permanent J-code effective Oct 1; >95% of Medicare payers now covering SYFOVRE.
- GALE extension study shows up to 45% reduction in nonsubfoveal GA lesion growth at Months 24-30 vs projected sham.
- Estimated retinal vasculitis rate remains rare at 0.01% per injection; 10 confirmed events, 2 suspected.

## SEC filing metadata
- accession: 0001193125-23-251073
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312523251073/0001193125-23-251073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312523251073/d555980d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-251073
- JSON: https://secwatch.observer/filing/0001193125-23-251073.json
- Plain text: https://secwatch.observer/filing/0001193125-23-251073.txt

## Key facts
- Earnings Releases
  Apellis Pharmaceuticals, Inc. reported third quarter of 2023 results: revenue approximately $74 million.
  - Period: third quarter of 2023
  - Revenue: approximately $74 million
  - Result: preliminary results
  source text: Apellis expects approximately $74 million in preliminary U.S. net product revenue for SYFOVRE in the third quarter and approximately $160 million in preliminary total U.S. net product revenue for SYFOVRE since launch in March 2023 through September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312523251073/0001193125-23-251073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.